nach oben

Current Infectious Disease Reports

Erschienen in:

23.09.2022 | Pediatric Infectious Diseases (I Brook, Section Editor)

Interventions for the Prevention and Treatment of Japanese Encephalitis

verfasst von: Rohan Chand Sahu, Teeja Suthar, Anchal Pathak, Keerti Jain

Erschienen in: Current Infectious Disease Reports | Ausgabe 11/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Japanese encephalitis (JE), a clinical indication of JE virus–induced brain inflammation, is the most prevalent cause of viral encephalitis in the world. This review gives a comprehensive update on the epidemiology, clinical features, therapeutic trials and approaches for preventing the spread of JE. It also outlines the different JE vaccines used in various countries and recommendations for administration of JE vaccines.

Recent Findings

According to the WHO, annual incidence of JE is estimated to be approximately 68,000 cases worldwide. It is widespread across Asia–Pacific, with a potential for worldwide transmission. In endemic locations, JE is believed to affect children below 6 years of age, but in newly affected areas, both adults and children are at risk due to a lack of protective antibodies. Various vaccines have been developed for the prevention of JE and are being administered in endemic countries.

Summary

JE is a neuroinvasive disease that causes symptoms ranging from simple fever to severe encephalitis and death. Despite a vast number of clinical trials on various drugs, there is still no complete cure available, and it can only be prevented by adequate vaccination. Various nanotechnological approaches for the prevention and treatment of JE are outlined in this review.

Nur mit Berechtigung zugänglich

Misra UK, Kalita J. Overview: Japanese encephalitis. Prog Neurobiol. 2010;91:108–20.CrossRef

Banerjee A, Tripathi A. Recent advances in understanding Japanese encephalitis. F1000Res. 2019;8. https://pubmed.ncbi.nlm.nih.gov/31781366/.

Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, present, and future of Japanese encephalitis. Emerg Infect Dis Centers for Disease Control and Prevention. 2009;15:1. /pmc/articles/PMC2660690/.

Kumar R. Prevention, diagnosis, and management of Japanese encephalitis in children. Pediatr Heal Med Ther. 2014;5:99.

Hills S, Martin R, Marfin A, Fischer M. Control of Japanese encephalitis in Asia: the time is now. Expert Rev Anti Infect Ther. NIH Public Access; 2014;12:901. /pmc/articles/PMC4594829/.

Japanese encephalitis. https://www.who.int/news-room/fact-sheets/detail/japanese-encephalitis.

Wang H, Liang G. Epidemiology of Japanese encephalitis: past, present, and future prospects. Ther Clin Risk Manag. 2015;11:435–48. https://pubmed.ncbi.nlm.nih.gov/25848290/.

Sharma KB, Vrati S, Kalia M. Pathobiology of Japanese encephalitis virus infection. Mol Aspects Med. 2021;81.

Japanese encephalitis - Chapter 4 - 2020 yellow book | Travelers’ Health | CDC. https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/japanese-encephalitis.

10.

Wittesjö B, Eitrem R, Niklasson B, Vene S, Mangiafico JA. Japanese encephalitis after a 10-day holiday in Bali. Lancet. Elsevier. 1995;345:856.

11.

Caramello P, Canta F, Balbiano R, Lipani F, Ariaudo S, De Agostini M, et al. A case of imported JE acquired during short travel in Vietnam. Are current recommendations about vaccination broader? J Travel Med Oxford Academic. 2007;14:346–8. https://academic.oup.com/jtm/article/14/5/346/1809058.

12.

• Kulkarni R, Sapkal G, Kaushal H, Mourya D. Japanese encephalitis: a brief review on Indian perspectives. Open Virol J. 2018;12:121–30. https://pubmed.ncbi.nlm.nih.gov/30288200/. Reports the major JE endemic areas in India.

13.

Murhekar M, Vivian Thangaraj J, Sadanandane C, Mittal M, Gupta N, Rose W, et al. Investigations of seasonal outbreaks of acute encephalitis syndrome due to Orientia tsutsugamushi in Gorakhpur region, India: a One Health case study. Indian J Med Res. 2021;153:375–81. https://pubmed.ncbi.nlm.nih.gov/33907001/.

14.

Solomon T, Ni H, Beasley DWC, Ekkelenkamp M, Cardosa MJ, Barrett ADT. Origin and evolution of Japanese encephalitis virus in Southeast Asia. J Virol Am Soc Microbiol. 2003;77:3091–8. https://journals.asm.org/journal/jvi.

15.

Roberts A, Gandhi S. Japanese encephalitis virus: a review on emerging diagnostic techniques. Front Biosci (Landmark Ed); 2020;25:1875–93. https://pubmed.ncbi.nlm.nih.gov/32472762/.

16.

K. Saxena S, Tiwari S, Saxena R, Mathur A, N. Nair MP. Japanese encephalitis virus: the complex biology of an emerging pathogen. Encephalitis. 2013.

17.

• Wang X, Li SH, Zhu L, Nian QG, Yuan S, Gao Q, et al. Near-atomic structure of Japanese encephalitis virus reveals critical determinants of virulence and stability. Nat Commun Springer, US. 2017;8:1–8. https://doi.org/10.1038/s41467-017-00024-6. Studied the structure of JEV through cryo-electron microscopy.CrossRef

18.

Vashist S, Bhullar D, Vrati S. La protein can simultaneously bind to both 3’- and 5’-noncoding regions of Japanese encephalitis virus genome. DNA Cell Biol. 2011;30:339–46. https://pubmed.ncbi.nlm.nih.gov/21294637/.

19.

• Turtle L, Solomon T. Japanese encephalitis-the prospects for new treatments. Nat Rev Neurol. 2018;14:298–313. Described the genetic structure of RNA in JEV.CrossRef

20.

Unni SK, Růžek D, Chhatbar C, Mishra R, Johri MK, Singh SK. Japanese encephalitis virus: from genome to infectome. Microbes Infect. 2011;13:312–21.CrossRef

21.

Seo HJ, Kim HC, Klein TA, Ramey AM, Lee JH, Kyung SG, et al. Molecular detection and genotyping of Japanese encephalitis virus in mosquitoes during a 2010 outbreak in the Republic of Korea. PLoS ONE. 2013;8:1–11.CrossRef

22.

Hurk AF van den, Ritchie SA, Mackenzie JS. Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev of Entomology. 2008;54:17–35. https://doi.org/10.1146/annurev.ento.54.110807.090510.

23.

Solomon T, Kneen R, Dung N, Khanh V, Thuy T, Ha D, et al. Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet (London, England). 1998;351:1094–7. https://pubmed.ncbi.nlm.nih.gov/9660579/.

24.

Solomon T, Winter P. Neurovirulence and host factors in flavivirus encephalitis--evidence from clinical epidemiology. Arch Virol Suppl. 2004;161–70. https://pubmed.ncbi.nlm.nih.gov/15119771/.

25.

Johnson RT, Intralawan P, Puapanwatton S. Japanese encephalitis: identification of inflammatory cells in cerebrospinal fluid. Ann Neurol. 1986;20:691–5.CrossRef

26.

Kumar R, Tripathi P, Baranwal M, Singh S, Tripathi S, Banerjee G. Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh. India Clin Infect Dis. 2009;48:400–6.CrossRef

27.

Hills S, Dabbagh A, Jacobson J, Marfin A, Featherstone D, Hombach J, et al. Evidence and rationale for the World Health Organization recommended standards for Japanese encephalitis surveillance. BioMed Central. 2009;9:214. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809064/.

28.

Wang G, Li H, Yang X, Guo T, Wang L, Zhao Z, et al. Guillain-Barré syndrome associated with JEV infection. N Engl J Med. 2020;383:1188–90. https://pubmed.ncbi.nlm.nih.gov/32937054/.

29.

Ravi V, Taly AB, Shankar SK, Shenoy PK, Desai A, Nagaraja D, et al. Association of Japanese encephalitis virus infection with Guillain-Barré syndrome in endemic areas of south India. Acta Neurol Scand. 1994;90:67–72. https://pubmed.ncbi.nlm.nih.gov/7941960/.

30.

Kumar R. Understanding and managing acute encephalitis. F1000Res. 2020;9. https://pubmed.ncbi.nlm.nih.gov/32047620/.

31.

Kumar R, Tripathi P, Singh S, Bannerji G. Clinical features in children hospitalized during the 2005 epidemic of Japanese encephalitis in Uttar Pradesh, India. Clin Infect Dis. 2006;43:123–31. https://pubmed.ncbi.nlm.nih.gov/16779737/.

32.

Solomon T, Dung N, Kneen R, Thao le T, Gainsborough M, Nisalak A, et al. Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis. Brain. 2002;125:1084–93. https://pubmed.ncbi.nlm.nih.gov/11960897/.

33.

Tiwari S, Singh R, Tiwari R, Dhole T. Japanese encephalitis: a review of the Indian perspective. Braz J Infect Dis. 2012;16:564–73. https://pubmed.ncbi.nlm.nih.gov/23141974/.

34.

Rayamajhi A, Ansari I, Ledger E, Bista KP, Impoinvil DE, Nightingale S, et al. Clinical and prognostic features among children with acute encephalitis syndrome in Nepal; a retrospective study. BioMed Central. 2011;11:1–12. https://bmcinfectdis.biomedcentral.com/articles/https://doi.org/10.1186/1471-2334-11-294.

35.

Ajibowo AO, Ortiz JF, Alli A, Halan T, Kolawole OA. Management of Japanese encephalitis: a current update. Cureus. 2021;13.

36.

Hoke CH, Vaughn DW, Nisalak A, Intralawan P, Poolsuppasit S, Jongsawas V, et al. Effect of high-dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus. J Infect Dis. 1992;165:631–7.CrossRef

37.

Singh DAK, Mehta DA, Kushwaha DKP, Pandey AK, Mittal DM, Sharma DB, et al. Minocycline trial in Japanese encephalitis: a double blind, randomized placebo study. Pediatr Rev Int J Pediatr Res. 2016;3:371–7. https://pediatrics.medresearch.in/index.php/ijpr/article/view/120/237.

38.

Kumar R, Basu A, Sinha S, Das M, Tripathi P, Jain A, et al. Role of oral minocycline in acute encephalitis syndrome in India - a randomized controlled trial. BMC Infect Dis. 2016;16:1–10. https://doi.org/10.1186/s12879-016-1385-6.CrossRef

39.

Rayamajhi A, Nightingale S, Bhatta NK, Singh R, Ledger E, Bista KP, et al. A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PLoS ONE. 2015;10:1–21. https://doi.org/10.1371/journal.pone.0122608.CrossRef

40.

Solomon T, Dung NM, Wills B, Kneen R, Gainsborough M, Diet TV, et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet. 2003;361:821–6.CrossRef

41.

Guo J, Jia X, Liu Y, Wang S, Cao J, Zhang B, et al. Screening of natural extracts for inhibitors against Japanese encephalitis virus infection. Antimicrob Agents Chemother. 2020;64:1–11.CrossRef

42.

Japanese encephalitis vaccines: WHO position paper - February 2015; 90:69–88. https://apps.who.int/iris/handle/10665/242325.

43.

Dubischar K, Kadlecek V, Sablan B, Borja-Tabora C, Gatchalian S, Eder-Lingelbach S, et al. Safety of the inactivated Japanese encephalitis virus vaccine IXIARO in children: an open-label, randomized, active-controlled, phase 3 study. Pediatr Infect Dis J. 2017;36:889–97. https://pubmed.ncbi.nlm.nih.gov/28441266/.

44.

Vadrevu K, Potula V, Khalatkar V, Mahantshetty N, Shah A, Ella R. Persistence of immune responses with an inactivated Japanese encephalitis single-dose vaccine, JENVAC and interchangeability with a live-attenuated vaccine. J Infect Dis. 2020;222:1478–87. https://pubmed.ncbi.nlm.nih.gov/31858116/.

45.

Hegde N, Gore M. Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. Hum Vaccin Immunother. 2017;13:1320–37. https://pubmed.ncbi.nlm.nih.gov/28301270/.

46.

Batchelor P, Petersen K. Japanese encephalitis: a review of clinical guidelines and vaccine availability in Asia. Trop Dis Travel Med Vaccines BioMed Central. 2015;1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530929/.

47.

Satchidanandam V. Japanese encephalitis vaccines. Curr Treat Options Infect Dis. 2020;12:375–86. http://link.springer.com/https://doi.org/10.1007/s40506-020-00242-5.

48.

• Kumar A, Sharma P, Shukla KK, Misra S, Nyati KK. Japanese encephalitis virus: associated immune response and recent progress in vaccine development. Microb Pathog. Elsevier Ltd. 2019;136:103678. https://doi.org/10.1016/j.micpath.2019.103678. This review povides a brief description on different JE vaccines.

49.

Muangchana C, Henprasertthae N, Nurach K, Theppang K, Yoocharoen P, Varinsathien P, et al. Effectiveness of mouse brain-derived inactivated Japanese encephalitis vaccine in Thai National Immunization Program: a case-control study. Vaccine Elsevier Ltd. 2012;30:361–7. https://doi.org/10.1016/j.vaccine.2011.10.083.CrossRef

50.

Plesner AM. Allergic reactions to Japanese encephalitis vaccine. Immunol Allergy Clin North Am Elsevier. 2003;23:665–97.CrossRef

51.

IXIARO | FDA https://www.fda.gov/vaccines-blood-biologics/vaccines/ixiaro.

52.

Food and Drug Administration. Ixiaro: Japanese encephalitis vaccine, inactivated, adsorbed [package insert]. Vienna, Austria: Valneva Austria GmbH; 2018 https://www.google.com/search?q=Food+and+Drug+Administration.+Ixiaro%3A+Japanese+encephalitis+vaccine%2C+inactivated%2C+adsorbed+%5Bpackage+insert%5D.+Vienna%2C+Austria%3A+Valneva+Austria+GmbH%3B+2018&rlz=1C1CHBF_enIN945IN945&oq=Food+and+Drug+Administrati.

53.

Schuller E, Klingler A, Dubischar-Kastner K, Dewasthaly S, Müller Z. Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO(®).Vaccine; 2011;29:8669–76. https://pubmed.ncbi.nlm.nih.gov/21907747/.

54.

Dubischar KL, Kadlecek V, Sablan B, Borja-Tabora CF, Gatchalian S, Eder-Lingelbach S, et al. Safety of the inactivated Japanese encephalitis virus vaccine IXIARO in children: an open-label, randomized, active-controlled, phase 3 study. Pediatr. Infect. Dis. J. 2017.

55.

Ni H, Burns NJ, Chang GJJ, Zhang MJ, Wills MR, Trent DW, et al. Comparison of nucleotide and deduced amino acid sequence of the 5’ non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives. J Gen Virol. 1994;75:1505–10.CrossRef

56.

Yongxin Y. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine. 2010;28:3635–41.CrossRef

57.

Ranganath BG, Hiremath SG. Adverse events following immunisation with SA 14–14-2 Japanese encephalitis vaccine in children of Kolar in Karnataka. J Indian Med Assoc. 2012;110:10–2.

58.

Chotpitayasunondh T, Sohn YM, Yoksan S, Min J, Ohrr H. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand. J Med Assoc Thai. 2011;94(Suppl):3.

59.

Zaman K, Naser AM, Power M, Yaich M, Zhang L, Ginsburg AS, et al. Lot-to-lot consistency of live attenuated SA 14–14-2 Japanese encephalitis vaccine manufactured in a good manufacturing practice facility and non-inferiority with respect to an earlier product. Vaccine. 2014;32:6061–6.CrossRef

60.

Sanchayan K, Fernandopulle R, Amarasinghe A, Thiyahiny S, Sri Ranganathan S. Safety of live attenuated Japanese encephalitis vaccine given at the age of 9 months in National Immunisation Programme of Sri Lanka. Ceylon Med J. 2016;61:99–105. https://pubmed.ncbi.nlm.nih.gov/27727408/.

61.

Upreti SR, Janusz KB, Schluter WW, Bichha RP, Shakya G, Biggerstaff BJ, et al. Estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA 14–14-2 vaccine in Nepal. Am J Trop Med Hyg. 2013;88:464–8.CrossRef

62.

Kumar R, Tripathi P, Rizvi A. Effectiveness of one dose of SA 14–14-2 vaccine against Japanese encephalitis. N Engl J Med. 2009;360:1465–6.CrossRef

63.

Feroldi E, Pancharoen C, Kosalaraksa P, Chokephaibulkit K, Boaz M, Meric C, et al. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14–14–2: a randomized study of immunogenicity and safety. Pediatr Infect Dis J. 2014;33:643–9. https://pubmed.ncbi.nlm.nih.gov/24717964/.

64.

Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol. 1999;73:3095–101. https://pubmed.ncbi.nlm.nih.gov/10074160/.

65.

Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, Delagrave S, et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine. 1999;17:1869–82.CrossRef

66.

Connor B, Bunn WB. The changing epidemiology of Japanese encephalitis and new data: the implications for New recommendations for Japanese encephalitis vaccine. Trop Dis Travel Med Vaccines. 2017;3:1–6.

67.

• Hills SL, Walter EB, Atmar RL, Fischer M. Japanese encephalitis vaccine: recommendations of the advisory committee on immunization practices. MMWR Recomm. Reports. 2019. This review outlines the recommendations for administration of JE vaccines.

68.

Lee PI, Huang YC, Hwang KP, Liu CC, Chiu CH, Chen PY, et al. Recommendations for the use of Japanese encephalitis vaccines. Pediatr Neonatol. Elsevier Taiwan LLC; 2020;61:3–8. Available from: https://doi.org/10.1016/j.pedneo.2019.11.009.

69.

Upreti SR, Lindsey NP, Bohara R, Choudhary GR, Shakya S, Gautam M, et al. Updated estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA 14–14–2 vaccine in Nepal. PLoS Negl Trop Dis Public Library of Science. 2017;11:e0005866. https://journals.plos.org/plosntds/article?id=https://doi.org/10.1371/journal.pntd.0005866.

70.

Heffelfinger JD, Li X, Batmunkh N, Grabovac V, Diorditsa S, Liyanage JB, et al. Japanese encephalitis surveillance and immunization - Asia and Western Pacific regions, 2016. Centers for Disease Control MMWR Office. 2019;66:579–83. https://www.facebook.com/CDCMMWR.

71.

Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89. https://pubmed.ncbi.nlm.nih.gov/22084515/.

72.

Mansfield K, Hernández-Triana L, Banyard A, Fooks A, Johnson N. Japanese encephalitis virus infection, diagnosis and control in domestic animals. Vet Microbiol. 2017;201:85–92. https://pubmed.ncbi.nlm.nih.gov/28284628/.

73.

Fischer M, Hills S, Staples E, Johnson B, Yaich M, Solomon T. Japanese encephalitis prevention and control: advances, challenges, and new initiatives. Emerg Infect. 2014;8:93–124.

74.

Morbidity JE. Accomplishments and lessons learned. Advocacy Japanese Enceph. 2009.

75.

Jain K, Ahmad J, Rizwanullah M, Suthar T, Albarqi HA, Ahmad MZ, et al. Receptor-targeted surface engineered nanomaterials for breast cancer imaging and theranostic applications. Crit Rev Ther Drug Carr Syst. Begel House Inc.. 2022. https://www.dl.begellhouse.com/references/3667c4ae6e8fd136,forthcoming,40686.html.

76.

Das B, Patra S. Antimicrobials: meeting the challenges of antibiotic resistance through nanotechnology. Nanostructures Antimicrob Ther Nanostructures Ther Med Ser. Elsevier. 2017;1–22.

77.

Juneja M, Suthar T, Pardhi VP, Ahmad J, Jain K. Emerging trends and promises of nanoemulsions in therapeutics of infectious diseases. 2022.

78.

Mba IE, Nweze EI. Application of nanotechnology in the treatment of infectious diseases: an overview. Nanotechnol Infect Dis Singapore: Springer, Singapore. 2022;25–51. https://doi.org/10.1007/978-981-16-9190-4_2.

79.

Duarte JL, Filippo LD Di, Araujo VHS, Oliveira AEM de FM, de Araújo JTC, Silva FB da R, et al. Nanotechnology as a tool for detection and treatment of arbovirus infections. Acta Trop. 2021;216.

80.

Jamkhande PG, Ghule NW, Bamer AH, Kalaskar MG. Metal nanoparticles synthesis: an overview on methods of preparation, advantages and disadvantages, and applications. J Drug Deliv Sci Technol. Elsevier. 2019;53:101174.

81.

• Chen H-H, Lin C-J, Anand A, Lin H-J, Lin H-Y, Mao J-Y, et al. Development of antiviral carbon quantum dots that target the Japanese encephalitis virus envelope protein. J Biol Chem Am Soc Biochem Mol Biol. 2022;101957. Available from: https://doi.org/10.1016/j.jbc.2022.101957. Proposes the use of nanotechnology in the treatment of JE infection.

82.

Govindarajan M, Rajeswary M, Veerakumar K, Muthukumaran U, Hoti SL, Benelli G. Green synthesis and characterization of silver nanoparticles fabricated using Anisomeles indica: mosquitocidal potential against malaria, dengue and Japanese encephalitis vectors. Exp Parasitol. Elsevier Inc. 2016;161:40–7. https://doi.org/10.1016/j.exppara.2015.12.011.

83.

• Gupta P, Preet S, Ananya, Singh N. Preparation of Thymus vulgaris (L.) essential oil nanoemulsion and its chitosan encapsulation for controlling mosquito vectors. Sci Rep. Nature Publishing Group UK. 2022;12:1–14. https://doi.org/10.1038/s41598-022-07676-5. Proposed nanotechnology-based method to effectively control the population of mosquito vectors in various infections.

84.

Huang HN, Li TL, Chan YL, Chen CL, Wu CJ. Transdermal immunization with low-pressure-gene-gun mediated chitosan-based DNA vaccines against Japanese encephalitis virus. Biomaterials Elsevier Ltd. 2009;30:6017–25. https://doi.org/10.1016/j.biomaterials.2009.07.029.CrossRef

Titel: Interventions for the Prevention and Treatment of Japanese Encephalitis
verfasst von: Rohan Chand Sahu
Teeja Suthar
Anchal Pathak
Keerti Jain
Publikationsdatum: 23.09.2022
Verlag: Springer US
Erschienen in: Current Infectious Disease Reports / Ausgabe 11/2022
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-022-00786-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Interventions for the Prevention and Treatment of Japanese Encephalitis

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2022

Correction to: Les misérables: A Parallel Between Antimicrobial Resistance and COVID‑19 in Underdeveloped and Developing Countries

Correction to: Nosocomial Extracardiac Infections After Cardiac Surgery

Les misérables: a Parallel Between Antimicrobial Resistance and COVID-19 in Underdeveloped and Developing Countries

No Crystal Ball? Using Risk Factors and Scoring Systems to Predict Extended-Spectrum Beta-Lactamase Producing Enterobacterales (ESBL-E) and Carbapenem-Resistant Enterobacterales (CRE) Infections

Nosocomial Extracardiac Infections After Cardiac Surgery

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin